Small-Molecule Inhibitors of Amyloid Beta: Insights from Molecular Dynamics-Part B: Natural Compounds

Area of Science:

• Neuroscience and Pharmacology
• Computational Biology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a progressive dementia characterized by amyloid beta (Aβ) plaques and tau tangles.
• The amyloid cascade hypothesis posits Aβ aggregation as the primary driver of AD pathogenesis.
• Understanding AD mechanisms is crucial for developing effective treatments.

Purpose of the Study:

• To review current findings on natural compounds with anti-amyloidogenic potential using molecular dynamics (MD) simulations.
• To analyze the inhibitory mechanisms of these natural compounds based on their structural features.
• To build upon previous work focusing on endogenous compounds and repurposed drugs.

Main Methods:

• Molecular dynamics (MD) simulations to study biomolecular motions at the atomic level.
• Analysis of Aβ oligomeric structures and their stabilizing interactions.
• Categorization of natural compounds by structural features to understand inhibitory mechanisms.

Main Results:

• MD simulations provide atomic-level insights into molecular properties, functions, and inhibition mechanisms of natural compounds.
• Natural compounds show potential for AD treatment and prevention due to their pharmacological activities and safety profiles.
• Specific structural features of natural compounds correlate with their anti-amyloidogenic activity.

Conclusions:

• Natural compounds, investigated via MD simulations, offer promising therapeutic strategies against Alzheimer's disease.
• MD simulations are vital for structure-based drug design and understanding drug-target interactions in AD.
• Further research into natural compounds could lead to novel AD treatments and preventive measures.